tetano
Editor, Senior Moderator
J Appl Microbiol
. 2022 Jan 26.
doi: 10.1111/jam.15463. Online ahead of print.
Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization
Floriana Bonura[SUP] 1 [/SUP], Simona De Grazia[SUP] 1 [/SUP], Celestino Bonura[SUP] 1 [/SUP], Giuseppa L Sanfilippo[SUP] 1 [/SUP], Giovanni M Giammanco[SUP] 1 [/SUP], Emanuele Amodio[SUP] 1 [/SUP], Donatella Ferraro[SUP] 1 [/SUP]
Affiliations
Abstract
Aims: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has had a serious worldwide impact on human health. At December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting health care workers (HCWs). This study aims to investigate the antibodies response against SARS-CoV-2 vaccine.
Methods and results: The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigate in 76 HCWs, through a four-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three different stages, with an initial slow growth in the anti-S1/S2 IgGs and Nt-Abs titres, corresponding to the first four weeks after the first dose of vaccine, followed by a second stage with peaks in titres, around 35 days after the first dose, and by a third stage (38 to 90-120 days after the first dose) showing a steady decrease in anti-S1/S2 IgGs while Nt-Abs are maintained at stable levels. Moreover, the levels of specific Nt-Abs to SARS-CoV-2 Spike protein are correlated to the anti-S1/S2 IgG titre (R- squared= 0.47; p<0.001).
Conclusions: The levels of specific Nt-Abs to SARS-CoV-2 Spike protein are correlated to the anti-S1/S2 IgG titre, although Nt-Abs could maintain a more stable titre over the time despite declining IgG Abs titre.
Significance and impact: This study highlights the kinetics and the persistence of Nt-Abs in HCWs vaccinated with Comirnaty (BNT162b2) Pfizer-BioNTech, and compared the Nt-Abs levels to anti-SARS-CoV-2 S1/S2 IgGs titres during a four-month follow-up starting at the first dose of vaccine.
Keywords: Italy; SARS-CoV-2; health-care workers; kinetics of antibodies; neutralizing antibodies.
. 2022 Jan 26.
doi: 10.1111/jam.15463. Online ahead of print.
Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization
Floriana Bonura[SUP] 1 [/SUP], Simona De Grazia[SUP] 1 [/SUP], Celestino Bonura[SUP] 1 [/SUP], Giuseppa L Sanfilippo[SUP] 1 [/SUP], Giovanni M Giammanco[SUP] 1 [/SUP], Emanuele Amodio[SUP] 1 [/SUP], Donatella Ferraro[SUP] 1 [/SUP]
Affiliations
- PMID: 35083832
- DOI: 10.1111/jam.15463
Abstract
Aims: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has had a serious worldwide impact on human health. At December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting health care workers (HCWs). This study aims to investigate the antibodies response against SARS-CoV-2 vaccine.
Methods and results: The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigate in 76 HCWs, through a four-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three different stages, with an initial slow growth in the anti-S1/S2 IgGs and Nt-Abs titres, corresponding to the first four weeks after the first dose of vaccine, followed by a second stage with peaks in titres, around 35 days after the first dose, and by a third stage (38 to 90-120 days after the first dose) showing a steady decrease in anti-S1/S2 IgGs while Nt-Abs are maintained at stable levels. Moreover, the levels of specific Nt-Abs to SARS-CoV-2 Spike protein are correlated to the anti-S1/S2 IgG titre (R- squared= 0.47; p<0.001).
Conclusions: The levels of specific Nt-Abs to SARS-CoV-2 Spike protein are correlated to the anti-S1/S2 IgG titre, although Nt-Abs could maintain a more stable titre over the time despite declining IgG Abs titre.
Significance and impact: This study highlights the kinetics and the persistence of Nt-Abs in HCWs vaccinated with Comirnaty (BNT162b2) Pfizer-BioNTech, and compared the Nt-Abs levels to anti-SARS-CoV-2 S1/S2 IgGs titres during a four-month follow-up starting at the first dose of vaccine.
Keywords: Italy; SARS-CoV-2; health-care workers; kinetics of antibodies; neutralizing antibodies.